Director Nicholas Liveris updates Novonix (NVX) shareholding in ASX notice

Rhea-AI Filing Summary

Novonix Limited filed a Form 6-K reporting a change in director shareholdings via an attached ASX Appendix 3Y. The notice covers director Nicholas Liveris, whose interest is recorded as a direct holding following an on-market trade. After this change, he holds 459,090 ordinary shares in Novonix.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

001-41208

(Commission File Number)

NOVONIX LIMITED

(Translation of registrant’s name into English)

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No. Description

Exhibit 99.1 Appendix 3Y (Change of Director's Interest Notice) dated March 16, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVONIX LIMITED

By: /s/ Robert Long

       Robert Long

       Chief Executive Officer

Date: March 16, 2026

EXHIBIT 99.1

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NOVONIX LIMITED

ABN 54 157 690 830

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	NICHOLAS LIVERIS
Date of last notice	12 March 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	13 March 2026
No. of securities held prior to change	559,090 Ordinary shares
Class	Ordinary shares
Number acquired	Nil
Number disposed	100,000 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$28,275.32

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

EXHIBIT 99.1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change	459,090 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

EXHIBIT 99.1

Appendix 3Y Change of Director’s Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

FAQ

What does Novonix (NVX) report in this March 2026 Form 6-K?

Novonix reports a change in director shareholdings through an attached ASX Appendix 3Y. The filing records updated interests for director Nicholas Liveris following an on-market trade and confirms his total direct holding after the change.

Which Novonix (NVX) director is covered by the Appendix 3Y notice?

The Appendix 3Y notice covers director Nicholas Liveris. It updates his relevant interests in Novonix securities, confirming his direct holding and stating that the change in his position resulted from an on-market trade in the company’s ordinary shares.

How many Novonix (NVX) shares does Nicholas Liveris hold after the change?

After the reported change, Nicholas Liveris holds 459,090 ordinary shares in Novonix. This figure is explicitly recorded as the number of securities held after the on-market trade disclosed in the Appendix 3Y attached to the Form 6-K.

Was the Novonix (NVX) director trade during a closed period?

The filing states the interests were not traded during a closed period requiring prior written clearance. The relevant section of the Appendix 3Y confirms the answer "No" to trading during a closed period for this director transaction.

What type of transaction changed the Novonix (NVX) director’s holding?

The change in the director’s relevant interest arose from an on-market trade. This is explicitly identified in the Appendix 3Y as the nature of the change affecting director Nicholas Liveris’s directly held ordinary shares in Novonix.

Does the Novonix (NVX) filing mention any director contracts affected?

The notice indicates there is no change in director interests in contracts. In Part 2 of the Appendix 3Y, the detail of contract field is marked "N/A," showing no separate contract-based interests were reported or amended in this disclosure.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 61.2 KB